Aubrey Capital Management Ltd Grows Stock Holdings in Natera, Inc. $NTRA

Key Points

• Aubrey Capital Management Ltd boosted its Natera stake by 32.1% in the fourth quarter, buying 5,200 additional shares and bringing its holding to 21,400 shares valued at about $4.9 million.
• Natera’s recent operating results were strong, with first-quarter revenue of $696.6 million up 38.8% year over year and a gross margin of 64.7%, while revenue guidance for 2026 was raised to $2.7 billion-$2.8 billion.
• Wall Street remains broadly positive on the stock, with several firms raising price targets and the consensus rating sitting at “Moderate Buy,” though insider selling and continued losses remain notable concerns.

Aubrey Capital Management Ltd increased its stake in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 32.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 21,400 shares of the medical research company's stock after buying an additional 5,200 shares during the period. Natera comprises 1.9% of Aubrey Capital Management Ltd's portfolio, making the stock its 14th largest holding. Aubrey Capital Management Ltd's holdings in Natera were worth $4,902,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. Flagship Harbor Advisors LLC purchased a new stake in Natera during the fourth quarter worth about $41,000. Horizon Investments LLC purchased a new stake in shares of Natera in the third quarter valued at about $32,000. TD Waterhouse Canada Inc. purchased a new stake in shares of Natera in the fourth quarter valued at about $62,000. Sound Income Strategies LLC lifted its holdings in shares of Natera by 20.0% in the fourth quarter. Sound Income Strategies LLC now owns 270 shares of the medical research company's stock valued at $62,000 after purchasing an additional 45 shares in the last quarter. Finally, Quent Capital LLC purchased a new stake in shares of Natera in the third quarter valued at about $46,000. Hedge funds and other institutional investors own 99.90% of the company's stock.

Trending Headlines about Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: JPMorgan raised its price target on Natera to $265 from $260 and kept an overweight rating, signaling confidence in further upside from current levels. JPMorgan raises Natera price target
• Positive Sentiment: Wells Fargo also lifted its target to $220 from $215, indicating continued analyst support despite a more neutral equal-weight stance. Wells Fargo raises Natera price target
• Positive Sentiment: First-quarter revenue came in well above expectations at $696.6 million, up 38.8% year over year, and the company also reported gross margin of 64.7%, showing strong top-line growth. Natera Q1 results
• Neutral Sentiment: Natera updated full-year 2026 revenue guidance to $2.7 billion-$2.8 billion, roughly in line with consensus, which suggests the outlook is steady but not a major surprise. Natera guidance update
• Negative Sentiment: Profitability remains a concern: Natera posted a quarterly loss of $0.60 per share, wider than the expected $0.53 loss, despite the revenue beat. Natera earnings miss
• Negative Sentiment: Recent insider selling, including a CEO stock sale, may add pressure by reinforcing concerns about valuation after the stock’s strong run. Natera CEO stock sale

Natera Stock Performance

NTRA opened at $194.24 on Monday. The firm has a market cap of $27.64 billion, a price-to-earnings ratio of -119.17 and a beta of 1.57. Natera, Inc. has a twelve month low of $131.81 and a twelve month high of $256.36. The company has a fifty day simple moving average of $202.23 and a 200 day simple moving average of $215.02.

Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings data on Thursday, February 26th. The medical research company reported $0.35 earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.81. The company had revenue of $665.50 million during the quarter, compared to analyst estimates of $600.68 million. Natera had a negative net margin of 9.05% and a negative return on equity of 15.72%. During the same period last year, the business earned ($0.41) EPS. On average, analysts forecast that Natera, Inc. will post -1.71 earnings per share for the current fiscal year.

Insider Activity at Natera

In other Natera news, insider Solomon Moshkevich sold 3,405 shares of the firm's stock in a transaction on Friday, May 1st. The shares were sold at an average price of $203.69, for a total transaction of $693,564.45. Following the completion of the transaction, the insider directly owned 142,295 shares of the company's stock, valued at $28,984,068.55. This trade represents a 2.34% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Steven Leonard Chapman sold 5,838 shares of the firm's stock in a transaction on Monday, April 27th. The stock was sold at an average price of $204.14, for a total transaction of $1,191,769.32. Following the transaction, the chief executive officer directly owned 150,769 shares of the company's stock, valued at approximately $30,777,983.66. This represents a 3.73% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 38,266 shares of company stock valued at $7,747,808 in the last 90 days. 5.63% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

NTRA has been the topic of several recent research reports. Evercore reaffirmed an "outperform" rating and issued a $270.00 price target on shares of Natera in a report on Friday. Robert W. Baird set a $265.00 price objective on shares of Natera in a research note on Friday. William Blair started coverage on shares of Natera in a research note on Tuesday, April 14th. They set an "outperform" rating on the stock. Weiss Ratings reissued a "sell (d-)" rating on shares of Natera in a research note on Tuesday, April 21st. Finally, Canaccord Genuity Group reissued a "buy" rating on shares of Natera in a research note on Monday, January 12th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $256.00.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.